Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases

Chih-hung Lee, Takashi Kakinuma, Julia Wang, Hong Zhang, Douglas C. Palmer, Nicholas P. Restifo and Sam T. Hwang
Chih-hung Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Kakinuma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas C. Palmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas P. Restifo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam T. Hwang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-06-0310 Published October 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    CXCR4 activation does not protect CXCR4-B16 from cell death induced by cyclophosphamide. CXCR4-luc-B16 cells were seeded in six-well plates (1.5 × 105 per well) in DMEM with 0.5% FCS. On reaching 30% confluence, the cells were treated with CXCL12 (1 μg/mL) overnight if indicated. Cells were then treated with cyclophosphamide at the indicated concentrations for 24 h and then assessed for viability by the Annexin V assay. Representative of three experiments with similar results.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Activation of CXCR4 in B16 cells by CXCL12 prevents Fas-dependent pmel-1-induced cytotoxicity. A to C, after serum starvation and IFN-γ treatment, CXCR4-luc-B16 cells were labeled with calcein-AM and mixed with different ratios of pmel-1 cells (from WT as well as perforin- and FasL-deficient mice) for 3 h at 37°C in the presence of CXCL12, T22, zVAD-fmk (zVAD), and anti-FasL antibody. The supernatants were recovered and cell lysis fraction was calculated based on calcein release. The lysis fraction (%) was calculated by dividing the observed calcein release by the maximal (total) calcein release of the cells treated with 0.1% Triton X-100. A, pmel-1 cells from WT (⧫), WT with 100 μg/mL anti-FasL antibody (•), FasL knockout (▪), and perforin knockout mice (▴) were used. B, T22 was added to CXCR4-luc-B16 cells for 3 h at 37°C before treatment with CXCL12 (□). T22 was also added to CXCR4-luc-B16 cells without CXCL12 treatment (▪). C, luc-B16 cells were used as target cells in the presence of pmel-1 cells (⧫) with 1 μmol/L zVAD-fmk (•) or 1 μg/mL CXCL12 (▴). D, human MEL501A melanoma cells were serum starved overnight to increase CXCR4 expression, then treated with 1 mg/mL CXCL12 (▴), 1 μmol/L zVAD-fmk (•), 1 μg/mL T22 alone (▪), T22 + CXCL12 (□), or left untreated (⧫) overnight, labeled with calcein-AM, and then added to interleukin 2 (IL-2)–treated melanoma antigen–specific JR6C12 T cells at different E/T ratios for 3 h at 37°C. Percent cytotoxicity was calculated as for B16 cells. A to D, representative experiment from two or more experiments with consistent findings.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    CXCR4 inhibition by T22 potentiates cyclophosphamide in reducing established lung metastases of CXCR4-luc-B16 melanoma in vivo. CXCR4-luc-B16 cells (4 × 105 per mouse) were injected via tail vein of C57BL/6 mice (n = 5 per treatment group). Mice were euthanized on day 14 to measure luciferase activity in lungs. A, on day 5, the indicated doses of cyclophosphamide were administered i.p. to mice. B, in addition to cyclophosphamide treatment at 100 mg/kg on day 5, some of the mice were also treated with T22 40 μg (or the nonactive control peptide ALA, 40 μg) i.p. daily on day 4 to 7. Representative of three or more independent experiments. Luciferase activity is shown in relative light units.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    An intact immune system is required for T22 to synergize with cyclophosphamide. A and B, CXCR4-luc-B16 cells (4 × 105 per mouse) were injected into SCID/bge mice via tail vein. A, SCID/bge mice were treated with cyclophosphamide (100 mg/kg i.p.) on day 5. On day 14, tumor burden was assessed by measuring individual lung mass. Lungs from noninjected mice served as controls. B, SCID/bge mice were treated with cyclophosphamide (100 mg/kg i.p.) on day 5 with or without T22 (40 μg/mouse i.p.) daily on day 4 to 7. On day 14, lung tumor burden was measured by luciferase assay. The experiments depicted were done on different days with separate preparations of cells.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    T22 pretreatment is required for anti-CTLA4-mediated reduction of established tumor burden in the lungs. A and B, CXCR4-B16 cells were inoculated via the tail vein in WT mice (n = 4 mice per treatment group, otherwise as described in Fig. 3). T22, when used, was administered i.p. (40 μg/mouse) daily on day 3 to 7 and day 9 to 10. Anti-CTLA4 mAb (clone 9H10), when used, was administered i.p. (250 μg/mouse) on day 3, 6, and 9. When combination treatment was administered, T22 injections were given i.p. 2 h before injection of anti-CTLA4 mAb. Mice were euthanized on day 13 for visual inspection of lung metastases (representative lungs from one of four mice used per group; A) and quantitative in vitro measurement of luciferase activity (B). Columns, mean; bars, SE.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 5 (10)
October 2006
Volume 5, Issue 10
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
Chih-hung Lee, Takashi Kakinuma, Julia Wang, Hong Zhang, Douglas C. Palmer, Nicholas P. Restifo and Sam T. Hwang
Mol Cancer Ther October 1 2006 (5) (10) 2592-2599; DOI: 10.1158/1535-7163.MCT-06-0310

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
Chih-hung Lee, Takashi Kakinuma, Julia Wang, Hong Zhang, Douglas C. Palmer, Nicholas P. Restifo and Sam T. Hwang
Mol Cancer Ther October 1 2006 (5) (10) 2592-2599; DOI: 10.1158/1535-7163.MCT-06-0310
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
  • Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement